Article Text

Download PDFPDF
Lung alert
The inhibition of anaplastic lymphoma kinase in non-small cell lung tumours with the ALK rearrangement may result in tumour shrinkage
  1. Louise Hancock
  1. Correspondence to Dr Louise Hancock, North Middlesex Hospital, London, UK; lhancock{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In this study, the therapeutic efficacy of inhibiting anaplastic lymphoma kinase (ALK) in oncogenic fusion genes consisting of EML4 and ALK was explored in an early-phase clinical trail of crizotinib. Tumour samples from 1500 patients with non-small cell lung cancer (NSCLC) …

View Full Text